Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer

• Published in: The Annals of thoracic surgery Vol. 109; no. 3; pp. 842 - 847
• Main Authors: Rice, Jonathan D., Heidel, Justin, Trivedi, Jaimin R., van Berkel, Victor H.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-03-2020
• Subjects: Aged; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - therapy; Disease Progression; Female; Follow-Up Studies; Humans; Kentucky - epidemiology; Lung Neoplasms - diagnosis; Lung Neoplasms - mortality; Lung Neoplasms - therapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Operative Time; Pneumonectomy - methods; Prognosis; Retrospective Studies; Survival Rate - trends; Kentucky
• ISSN: 0003-4975; 1552-6259
• DOI: 10.1016/j.athoracsur.2019.09.076

Patients with clinically/pathologically diagnosed stage IIIa non-small cell lung cancer (NSCLC) considered for surgery are recommended to undergo neoadjuvant chemotherapy with or without radiation. The timing of an operation after therapy is not standardized; therefore, we investigated the timing of intervention after neoadjuvant therapy and the impact on outcomes in this demographic.
The National Cancer Database was queried between 2010 and 2015 for patients with clinical/pathologic stage IIIa NSCLC. Patients were then divided into short (<77 days), mid (77-114 days), and long delay (>114 days) groups based on interquartile values. These groups were then compared for age, race, gender, insurance type, Charlson-Deyo score, length of stay, readmission rate, and overall survival based on timing of operation.
There were 31,357 patients with clinical/pathologic stage IIIa NSCLC, and 5946 patients underwent surgical intervention. Preoperatively 3593 patients underwent chemoradiotherapy, 2185 underwent chemotherapy only, and 168 received radiation alone. The short, mid, and long delay groups were clinically and statistically similar in age, gender, insurance type, comorbidity index, treating facility type, and distance from home. Long delay groups had larger tumor size compared with other groups. Postoperative length of stay, rates of 30-day readmission, and 30- and 90-day mortality were similar across all groups. Cox modeling demonstrated a significant difference in survival when patients underwent earlier operative intervention compared with late operative intervention and when patients received chemoradiation compared with chemotherapy alone. Short, mid, and long delay group 1-year survivals were 82%, 83%, and 80% and 3-year survival 59%, 58%, and 52%, respectively (P = .0003).
The delay in surgical resection of stage IIIa NSCLC is not associated increased early mortality; however, it is associated with worse 3-year postresection survival.